1Niesters HG,de Man RA,Pas SD,et al.Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy[J].J Med Microbiol,2002,51(8):695-699.
3Lau DT,khokhar MF,Doo E,et al.Long-term therapy of chronic hepatitis B with lamivudine[J].Hepatology,2000,32 (4Pt 1):828-834.
4Tassopoulos NC,Volpes R,Pastore G,et al.Efficacy of lamivudine in patients with hepatitis B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B[J].Hepatology,1999,29 (3):889-896.
5Zollner B,Petersen J,Schroter M,et al.20-fold increase in risk of lamivudine resistance in hepatitis B virus subtype adw[J].Lancet,2001,357 (9260):934-935.
6Perrillo R,Rakela J,Dienstag J,et al.Multicenter study of lamivudine therapy for hepatitis B after liver transplantation[J].Hepatotogy,1999,29(5):1581-1586.
8Liaw YF,Leung NW,Chang TT,et al.Effects of extended lamivudine therapy in asian patients with chronic hepatitis B[J].Gastroenterology,2000,119(1):172-180.
9Malkan G,Cattral MS,Humar A,et al.Lamivudine for hepatitis B in liver transplantation:a single-center experience[J].Transplantation,2000,69 (7):1403-1407.
10Ben-Ari Z,Pappo O,Zemel R,et al.Association of lamivudine resistance in recurrent hepatitis B after liver transplantation with advanced hepatic fibrosis[J].Transplantation,1999,68(2):232-236.
二级参考文献19
1[1]Leung N W Y, Lai C L, Chang N T, et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy[J]. Hepatology, 2001, 33(6): 1 527-1 532.
2[2]Allen M I, Deslauriers M, Andrews C W, et al. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine[J]. Hepatology, 1998, 27(6): 1 670-1 677.
3[3]Santantonio T, Mazzola M, Iacovazzi T, et al. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine[J]. J Hepatol, 2000, 32(2): 300-306.
4[4]Whalley S A, Brown D, Teo C G, et al. Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy using the LightCycler[J]. J Clin Microbiol, 2001, 39(4): 1 456-1 459.
5[5]Paik Y H, Chung H Y, Ryu W S, et al. Emergence of YMDD motif mutant of hepatitis B virus during short-term lamivudine therapy in South Korea[J]. J Hepatol, 2001, 35(1): 92-98.
6[6]Kobayashi S, Ide T, Sata M. Detection of YMDD motif mutations in some lamivudine-untreated asymptomatic hepatitis B virus carriers[J]. J Hepatol, 2001,34(4): 584-586.
7Nordenfelt E, Helgstrand E, oberg B. Trisodium phosphonoformate inhibits B Dane particle DNA polymerase[J]. Acta Pathol Microbiol Scand. 1979.87B:75-76.
10Lai CL, Dienstag J, Schiff E, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B[J]. Ciin Infect Dis, 2003,36(6) :687-696.
